HER2 AS A PREDICTIVE BIOMARKER AND TREATMENT TARGET IN COLORECTAL CANCER
The authors of this review provide an overview of data regarding HER2 as a predictive biomarker and target for treatment among patients with metastatic colorectal cancer (mCRC). The use of anti-EGFR monoclonal antibodies has been associated with improved outcomes among patients with RAS wild-type mCRC, but not all patients respond to therapy. The prognosis of […]
HER2 AS A PREDICTIVE BIOMARKER AND TREATMENT TARGET IN COLORECTAL CANCER Read More »
